Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC By Ogkologos - April 30, 2026 168 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Trastuzumab Deruxtecan Leads to Longer PFS and OS Compared with Chemotherapy... July 14, 2022 Chaunté Lowe Has Competed In 4 Olympic Games, And Isn’t Letting... April 10, 2020 Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia September 16, 2020 Working Outdoors in the Sunshine May Lower Your Risk of Breast... February 18, 2021 Load more HOT NEWS Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients... Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer...
